Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,220
archived clinical trials in
HIV / AIDS

Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated:  12/31/1969
Northwestern University CRS (2701)
mi
from
Chicago, IL
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated: 12/31/1969
Northwestern University CRS (2701)
mi
from
Chicago, IL
Click here to add this to my saved trials
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated:  12/31/1969
Brigham and Women's Hosp. ACTG CRS (107)
mi
from
Boston, MA
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated: 12/31/1969
Brigham and Women's Hosp. ACTG CRS (107)
mi
from
Boston, MA
Click here to add this to my saved trials
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital ACTG CRS (101)
mi
from
Boston, MA
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital ACTG CRS (101)
mi
from
Boston, MA
Click here to add this to my saved trials
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated:  12/31/1969
NY Univ. HIV/AIDS CRS (401)
mi
from
New York, NY
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated: 12/31/1969
NY Univ. HIV/AIDS CRS (401)
mi
from
New York, NY
Click here to add this to my saved trials
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated:  12/31/1969
AIDS Care CRS (1108)
mi
from
Rochester, NY
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated: 12/31/1969
AIDS Care CRS (1108)
mi
from
Rochester, NY
Click here to add this to my saved trials
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated:  12/31/1969
University of Rochester ACTG CRS (1101)
mi
from
Rochester, NY
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated: 12/31/1969
University of Rochester ACTG CRS (1101)
mi
from
Rochester, NY
Click here to add this to my saved trials
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated:  12/31/1969
Unc Aids Crs
mi
from
Chapel Hill, NC
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated: 12/31/1969
Unc Aids Crs
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated:  12/31/1969
Duke Univ. Med. Ctr. Adult CRS (1601)
mi
from
Durham, NC
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated: 12/31/1969
Duke Univ. Med. Ctr. Adult CRS (1601)
mi
from
Durham, NC
Click here to add this to my saved trials
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated:  12/31/1969
Metro Health CRS (2503)
mi
from
Cleveland, OH
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated: 12/31/1969
Metro Health CRS (2503)
mi
from
Cleveland, OH
Click here to add this to my saved trials
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated:  12/31/1969
Pittsburgh CRS (1001)
mi
from
Pittsburgh, PA
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated: 12/31/1969
Pittsburgh CRS (1001)
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated:  12/31/1969
The Miriam Hospital ACTG CRS (2951)
mi
from
Providence, RI
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated: 12/31/1969
The Miriam Hospital ACTG CRS (2951)
mi
from
Providence, RI
Click here to add this to my saved trials
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated:  12/31/1969
UCLA CARE Center CRS (601)
mi
from
Los Angeles, CA
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated: 12/31/1969
UCLA CARE Center CRS (601)
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated:  12/31/1969
Stanford CRS (501)
mi
from
Palo Alto, CA
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated: 12/31/1969
Stanford CRS (501)
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated:  12/31/1969
Ucsf Aids Crs (801)
mi
from
San Francisco, CA
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated: 12/31/1969
Ucsf Aids Crs (801)
mi
from
San Francisco, CA
Click here to add this to my saved trials
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated:  12/31/1969
University of Colorado Hospital CRS (6101)
mi
from
Aurora, CO
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated: 12/31/1969
University of Colorado Hospital CRS (6101)
mi
from
Aurora, CO
Click here to add this to my saved trials
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated:  12/31/1969
Georgetown University CRS (GU CRS) (1008)
mi
from
Washington,
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated: 12/31/1969
Georgetown University CRS (GU CRS) (1008)
mi
from
Washington,
Click here to add this to my saved trials
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated:  12/31/1969
University of Miami AIDS CRS (901)
mi
from
Miami, FL
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated: 12/31/1969
University of Miami AIDS CRS (901)
mi
from
Miami, FL
Click here to add this to my saved trials
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated:  12/31/1969
Rush Univ. Med. Ctr. ACTG CRS (2702)
mi
from
Chicago, IL
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated: 12/31/1969
Rush Univ. Med. Ctr. ACTG CRS (2702)
mi
from
Chicago, IL
Click here to add this to my saved trials
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated:  12/31/1969
IHV Baltimore Treatment CRS (4651)
mi
from
Baltimore, MD
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated: 12/31/1969
IHV Baltimore Treatment CRS (4651)
mi
from
Baltimore, MD
Click here to add this to my saved trials
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated:  12/31/1969
Beth Israel Deaconess Med. Ctr., ACTG CRS (103)
mi
from
Boston, MA
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated: 12/31/1969
Beth Israel Deaconess Med. Ctr., ACTG CRS (103)
mi
from
Boston, MA
Click here to add this to my saved trials
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated:  12/31/1969
Washington U CRS (2101)
mi
from
Saint Louis, MO
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated: 12/31/1969
Washington U CRS (2101)
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated:  12/31/1969
New Jersey Medical School-Adult Clinical Research Ctr. CRS (31477)
mi
from
Newark, NJ
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated: 12/31/1969
New Jersey Medical School-Adult Clinical Research Ctr. CRS (31477)
mi
from
Newark, NJ
Click here to add this to my saved trials
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated:  12/31/1969
Cornell CRS (7804)
mi
from
New York, NY
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated: 12/31/1969
Cornell CRS (7804)
mi
from
New York, NY
Click here to add this to my saved trials
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated:  12/31/1969
HIV Prevention & Treatment CRS (30329)
mi
from
New York, NY
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated: 12/31/1969
HIV Prevention & Treatment CRS (30329)
mi
from
New York, NY
Click here to add this to my saved trials
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated:  12/31/1969
Univ. of Cincinnati CRS (2401)
mi
from
Cincinnati, OH
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated: 12/31/1969
Univ. of Cincinnati CRS (2401)
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated:  12/31/1969
Case CRS (2501)
mi
from
Cleveland, OH
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated: 12/31/1969
Case CRS (2501)
mi
from
Cleveland, OH
Click here to add this to my saved trials
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated:  12/31/1969
The Ohio State Univ. AIDS CRS (2301)
mi
from
Columbus, OH
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated: 12/31/1969
The Ohio State Univ. AIDS CRS (2301)
mi
from
Columbus, OH
Click here to add this to my saved trials
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated:  12/31/1969
Hosp. of the Univ. of Pennsylvania CRS (6201)
mi
from
Philadelphia, PA
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated: 12/31/1969
Hosp. of the Univ. of Pennsylvania CRS (6201)
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated:  12/31/1969
University of Washington AIDS CRS (1401)
mi
from
Seattle, WA
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated: 12/31/1969
University of Washington AIDS CRS (1401)
mi
from
Seattle, WA
Click here to add this to my saved trials
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated:  12/31/1969
Puerto Rico-AIDS CRS (5401)
mi
from
San Juan,
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Status: Enrolling
Updated: 12/31/1969
Puerto Rico-AIDS CRS (5401)
mi
from
San Juan,
Click here to add this to my saved trials
Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults
A Phase 1b Randomized Double-Blind Clinical Trial to Examine Whether Polytopic Administration of VRC rAd5 Gag-pol/Env A/B/C Vaccine Enhances HIV-Specific Cellular Immune Responses in Humans
Status: Enrolling
Updated:  12/31/1969
UIC Project WISH CRS
mi
from
Chicago, IL
Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults
A Phase 1b Randomized Double-Blind Clinical Trial to Examine Whether Polytopic Administration of VRC rAd5 Gag-pol/Env A/B/C Vaccine Enhances HIV-Specific Cellular Immune Responses in Humans
Status: Enrolling
Updated: 12/31/1969
UIC Project WISH CRS
mi
from
Chicago, IL
Click here to add this to my saved trials
Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults
A Phase 1b Randomized Double-Blind Clinical Trial to Examine Whether Polytopic Administration of VRC rAd5 Gag-pol/Env A/B/C Vaccine Enhances HIV-Specific Cellular Immune Responses in Humans
Status: Enrolling
Updated:  12/31/1969
Bridge HIV CRS
mi
from
San Francisco, CA
Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults
A Phase 1b Randomized Double-Blind Clinical Trial to Examine Whether Polytopic Administration of VRC rAd5 Gag-pol/Env A/B/C Vaccine Enhances HIV-Specific Cellular Immune Responses in Humans
Status: Enrolling
Updated: 12/31/1969
Bridge HIV CRS
mi
from
San Francisco, CA
Click here to add this to my saved trials
Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults
A Phase 1b Randomized Double-Blind Clinical Trial to Examine Whether Polytopic Administration of VRC rAd5 Gag-pol/Env A/B/C Vaccine Enhances HIV-Specific Cellular Immune Responses in Humans
Status: Enrolling
Updated:  12/31/1969
Brigham and Women's Hospital Vaccine CRS (BWH VCRS)
mi
from
Boston, MA
Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults
A Phase 1b Randomized Double-Blind Clinical Trial to Examine Whether Polytopic Administration of VRC rAd5 Gag-pol/Env A/B/C Vaccine Enhances HIV-Specific Cellular Immune Responses in Humans
Status: Enrolling
Updated: 12/31/1969
Brigham and Women's Hospital Vaccine CRS (BWH VCRS)
mi
from
Boston, MA
Click here to add this to my saved trials
Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults
A Phase 1b Randomized Double-Blind Clinical Trial to Examine Whether Polytopic Administration of VRC rAd5 Gag-pol/Env A/B/C Vaccine Enhances HIV-Specific Cellular Immune Responses in Humans
Status: Enrolling
Updated:  12/31/1969
Columbia P&S CRS
mi
from
New York, NY
Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults
A Phase 1b Randomized Double-Blind Clinical Trial to Examine Whether Polytopic Administration of VRC rAd5 Gag-pol/Env A/B/C Vaccine Enhances HIV-Specific Cellular Immune Responses in Humans
Status: Enrolling
Updated: 12/31/1969
Columbia P&S CRS
mi
from
New York, NY
Click here to add this to my saved trials
Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults
A Phase 1b Randomized Double-Blind Clinical Trial to Examine Whether Polytopic Administration of VRC rAd5 Gag-pol/Env A/B/C Vaccine Enhances HIV-Specific Cellular Immune Responses in Humans
Status: Enrolling
Updated:  12/31/1969
New York Blood Center CRS
mi
from
New York, NY
Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults
A Phase 1b Randomized Double-Blind Clinical Trial to Examine Whether Polytopic Administration of VRC rAd5 Gag-pol/Env A/B/C Vaccine Enhances HIV-Specific Cellular Immune Responses in Humans
Status: Enrolling
Updated: 12/31/1969
New York Blood Center CRS
mi
from
New York, NY
Click here to add this to my saved trials
Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults
A Phase 1b Randomized Double-Blind Clinical Trial to Examine Whether Polytopic Administration of VRC rAd5 Gag-pol/Env A/B/C Vaccine Enhances HIV-Specific Cellular Immune Responses in Humans
Status: Enrolling
Updated:  12/31/1969
University of Rochester Vaccines to Prevent HIV Infection CRS
mi
from
Rochester, NY
Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults
A Phase 1b Randomized Double-Blind Clinical Trial to Examine Whether Polytopic Administration of VRC rAd5 Gag-pol/Env A/B/C Vaccine Enhances HIV-Specific Cellular Immune Responses in Humans
Status: Enrolling
Updated: 12/31/1969
University of Rochester Vaccines to Prevent HIV Infection CRS
mi
from
Rochester, NY
Click here to add this to my saved trials
Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults
A Phase 1b Randomized Double-Blind Clinical Trial to Examine Whether Polytopic Administration of VRC rAd5 Gag-pol/Env A/B/C Vaccine Enhances HIV-Specific Cellular Immune Responses in Humans
Status: Enrolling
Updated:  12/31/1969
Penn Prevention Crs
mi
from
Philadelphia, PA
Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults
A Phase 1b Randomized Double-Blind Clinical Trial to Examine Whether Polytopic Administration of VRC rAd5 Gag-pol/Env A/B/C Vaccine Enhances HIV-Specific Cellular Immune Responses in Humans
Status: Enrolling
Updated: 12/31/1969
Penn Prevention Crs
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults
A Phase 1b Randomized Double-Blind Clinical Trial to Examine Whether Polytopic Administration of VRC rAd5 Gag-pol/Env A/B/C Vaccine Enhances HIV-Specific Cellular Immune Responses in Humans
Status: Enrolling
Updated:  12/31/1969
Vanderbilt Vaccine (VV) CRS
mi
from
Nashville, TN
Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults
A Phase 1b Randomized Double-Blind Clinical Trial to Examine Whether Polytopic Administration of VRC rAd5 Gag-pol/Env A/B/C Vaccine Enhances HIV-Specific Cellular Immune Responses in Humans
Status: Enrolling
Updated: 12/31/1969
Vanderbilt Vaccine (VV) CRS
mi
from
Nashville, TN
Click here to add this to my saved trials
Tobacco Assessment and Intervention With Low-Income Persons Living With HIV-AIDS (PLWHA) in Community-Based AIDS Service Organizations
Feasibility of Tobacco Assessment and Intervention With Low-Income Persons Living With HIV-AIDS (PLWHA) in Community-Based AIDS Service Organizations
Status: Enrolling
Updated:  12/31/1969
City College of New York
mi
from
New York, NY
Tobacco Assessment and Intervention With Low-Income Persons Living With HIV-AIDS (PLWHA) in Community-Based AIDS Service Organizations
Feasibility of Tobacco Assessment and Intervention With Low-Income Persons Living With HIV-AIDS (PLWHA) in Community-Based AIDS Service Organizations
Status: Enrolling
Updated: 12/31/1969
City College of New York
mi
from
New York, NY
Click here to add this to my saved trials
Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children
A Phase I/II, Open-Label Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Etravirine (ETR) in Antiretroviral (ARV) Treatment-Experienced HIV-1 Infected Infants and Children, Aged ≥ 2 Months to < 6 Years
Status: Enrolling
Updated:  12/31/1969
Pediatric Perinatal HIV Clinical Trials Unit CRS
mi
from
Miami, FL
Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children
A Phase I/II, Open-Label Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Etravirine (ETR) in Antiretroviral (ARV) Treatment-Experienced HIV-1 Infected Infants and Children, Aged ≥ 2 Months to < 6 Years
Status: Enrolling
Updated: 12/31/1969
Pediatric Perinatal HIV Clinical Trials Unit CRS
mi
from
Miami, FL
Click here to add this to my saved trials
Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children
A Phase I/II, Open-Label Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Etravirine (ETR) in Antiretroviral (ARV) Treatment-Experienced HIV-1 Infected Infants and Children, Aged ≥ 2 Months to < 6 Years
Status: Enrolling
Updated:  12/31/1969
Lurie Children's Hospital of Chicago (LCH) CRS
mi
from
Chicago, IL
Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children
A Phase I/II, Open-Label Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Etravirine (ETR) in Antiretroviral (ARV) Treatment-Experienced HIV-1 Infected Infants and Children, Aged ≥ 2 Months to < 6 Years
Status: Enrolling
Updated: 12/31/1969
Lurie Children's Hospital of Chicago (LCH) CRS
mi
from
Chicago, IL
Click here to add this to my saved trials
Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children
A Phase I/II, Open-Label Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Etravirine (ETR) in Antiretroviral (ARV) Treatment-Experienced HIV-1 Infected Infants and Children, Aged ≥ 2 Months to < 6 Years
Status: Enrolling
Updated:  12/31/1969
SOM Federal University Minas Gerais Brazil NICHD CRS
mi
from
Belo Horizonte,
Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children
A Phase I/II, Open-Label Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Etravirine (ETR) in Antiretroviral (ARV) Treatment-Experienced HIV-1 Infected Infants and Children, Aged ≥ 2 Months to < 6 Years
Status: Enrolling
Updated: 12/31/1969
SOM Federal University Minas Gerais Brazil NICHD CRS
mi
from
Belo Horizonte,
Click here to add this to my saved trials
Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children
A Phase I/II, Open-Label Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Etravirine (ETR) in Antiretroviral (ARV) Treatment-Experienced HIV-1 Infected Infants and Children, Aged ≥ 2 Months to < 6 Years
Status: Enrolling
Updated:  12/31/1969
Bronx-Lebanon Hospital Center NICHD CRS
mi
from
Bronx, NY
Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children
A Phase I/II, Open-Label Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Etravirine (ETR) in Antiretroviral (ARV) Treatment-Experienced HIV-1 Infected Infants and Children, Aged ≥ 2 Months to < 6 Years
Status: Enrolling
Updated: 12/31/1969
Bronx-Lebanon Hospital Center NICHD CRS
mi
from
Bronx, NY
Click here to add this to my saved trials
Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children
A Phase I/II, Open-Label Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Etravirine (ETR) in Antiretroviral (ARV) Treatment-Experienced HIV-1 Infected Infants and Children, Aged ≥ 2 Months to < 6 Years
Status: Enrolling
Updated:  12/31/1969
Jacobi Med. Ctr. Bronx NICHD CRS
mi
from
Bronx, NY
Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children
A Phase I/II, Open-Label Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Etravirine (ETR) in Antiretroviral (ARV) Treatment-Experienced HIV-1 Infected Infants and Children, Aged ≥ 2 Months to < 6 Years
Status: Enrolling
Updated: 12/31/1969
Jacobi Med. Ctr. Bronx NICHD CRS
mi
from
Bronx, NY
Click here to add this to my saved trials
Inflammation, Viral Replication, and Atherosclerosis in Treated HIV Infection
Immunologic and Inflammatory Factors and Cardiovascular Risk in Patients With HIV Infection or Autoimmune Diseases
Status: Enrolling
Updated:  12/31/1969
University of California, San Francisco, San Francisco General Hospital
mi
from
San Francisco, CA
Inflammation, Viral Replication, and Atherosclerosis in Treated HIV Infection
Immunologic and Inflammatory Factors and Cardiovascular Risk in Patients With HIV Infection or Autoimmune Diseases
Status: Enrolling
Updated: 12/31/1969
University of California, San Francisco, San Francisco General Hospital
mi
from
San Francisco, CA
Click here to add this to my saved trials
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
A Phase II Trial of Reduced Intensity Allogeneic Stem Cell Transplantation With Fludarabine, Melphalan and Low Dose Total Body Irradiation
Status: Enrolling
Updated:  12/31/1969
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
A Phase II Trial of Reduced Intensity Allogeneic Stem Cell Transplantation With Fludarabine, Melphalan and Low Dose Total Body Irradiation
Status: Enrolling
Updated: 12/31/1969
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Sevelamer for Reducing Endotoxemia and Immune Activation
Sevelamer Carbonate for Reducing Endotoxemia and Immune Activation: A Proof of Concept Study
Status: Enrolling
Updated:  12/31/1969
Alabama Therapeutics CRS (5801)
mi
from
Birmingham, AL
Sevelamer for Reducing Endotoxemia and Immune Activation
Sevelamer Carbonate for Reducing Endotoxemia and Immune Activation: A Proof of Concept Study
Status: Enrolling
Updated: 12/31/1969
Alabama Therapeutics CRS (5801)
mi
from
Birmingham, AL
Click here to add this to my saved trials
Sevelamer for Reducing Endotoxemia and Immune Activation
Sevelamer Carbonate for Reducing Endotoxemia and Immune Activation: A Proof of Concept Study
Status: Enrolling
Updated:  12/31/1969
UCLA CARE Center CRS (601)
mi
from
Los Angeles, CA
Sevelamer for Reducing Endotoxemia and Immune Activation
Sevelamer Carbonate for Reducing Endotoxemia and Immune Activation: A Proof of Concept Study
Status: Enrolling
Updated: 12/31/1969
UCLA CARE Center CRS (601)
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Sevelamer for Reducing Endotoxemia and Immune Activation
Sevelamer Carbonate for Reducing Endotoxemia and Immune Activation: A Proof of Concept Study
Status: Enrolling
Updated:  12/31/1969
University of Colorado Hospital CRS (6101)
mi
from
Aurora, CO
Sevelamer for Reducing Endotoxemia and Immune Activation
Sevelamer Carbonate for Reducing Endotoxemia and Immune Activation: A Proof of Concept Study
Status: Enrolling
Updated: 12/31/1969
University of Colorado Hospital CRS (6101)
mi
from
Aurora, CO
Click here to add this to my saved trials
Sevelamer for Reducing Endotoxemia and Immune Activation
Sevelamer Carbonate for Reducing Endotoxemia and Immune Activation: A Proof of Concept Study
Status: Enrolling
Updated:  12/31/1969
Northwestern University CRS (2701)
mi
from
Chicago, IL
Sevelamer for Reducing Endotoxemia and Immune Activation
Sevelamer Carbonate for Reducing Endotoxemia and Immune Activation: A Proof of Concept Study
Status: Enrolling
Updated: 12/31/1969
Northwestern University CRS (2701)
mi
from
Chicago, IL
Click here to add this to my saved trials